Sector: health
Conviction from: NASDAQCitrini
52-week range: 42.18224.31
Revolution Medicines is a clinical-stage oncology company developing targeted therapies against RAS and related cancer-driving mutations.
6 tracked filer(s) hold this · 1 opened, 3 added, 2 trimmed in 30-JUN-2026
Aggregate 13FScore 66 — mean of 6 scored holder(s) · buyers (new/add) avg 74. Higher = the smart money in this name has the better track record.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|
| Howard Marks / Oaktree | 71 | New buy | 1,150,000 | $1,442,773 | 0.0% |
| Stanley Druckenmiller / Duquesne | 95 | Added +27% | 399,587 | $74,835 | 1.4% |
| Louis Bacon / Moore | 53 | Added +47% | 81,700 | $15,300,776 | 0.2% |
| Steve Cohen / Point72 | 76 | Added +2999% | 80,576 | $15,090,273 | 0.0% |
| Ancora | 40 | Trimmed -93% | 20 | $3,746 | 0.0% |
| Paul Tudor Jones / Tudor | 63 | Trimmed -49% | 44,500 | $8,333,960 | 0.0% |
Beyond 13F — activists, insiders, politicians & research
4 disclosed trade(s) by 1 filer(s).
| Trade date | Who | Type | Amount | |
|---|
| 2026-09-22 | Trump, Donald J President | BUY | $1,001 - $15,000 | PTR |
| 2026-08-22 | Trump, Donald J President | BUY | $1,001 - $15,000 | PTR |
| 2026-07-01 | Trump, Donald J President | SELL | $50,001 - $100,000 | PTR |
| 2026-05-14 | Trump, Donald J President | BUY | $1,001 - $15,000 | PTR |
| Report | Date | Stance |
|---|
| #124 — State of the Themes: June 2026 | 2026-06-01 | LONG |